Therefore, AR is considered to be the most relevant therapeutic target for both hormone‐sensitive prostate cancer (HSPC) and advanced PCa (Crawford et al., 2015; Crona and Whang, 2017). This evidence concerns the gene AR and posterior cortical atrophy.